Cushing's syndrome induced by misuse of moderate- to high-potency topical corticosteroids

Annals of Pharmacotherapy

Volumn 42, Issue 12, 2008, Pages 1903-1907

  Coureau, Bénédicte ^a   Bussières, Jean François ^b,c,d   Tremblay, Stéphanie ^b,c  

^a Centre Hospitalier de Martigues   (France)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d NONE   (Canada)

Author keywords

Cushing's syndrome; Growth retardation; Hypothalamic pituitary adrenal axis suppression; Topical corticosteroids

Indexed keywords

AMLODIPINE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CEFALEXIN; CLOBETASOL PROPIONATE; CORTICOSTEROID; DESONIDE; DIPHENHYDRAMINE; DOXEPIN; HYDROCORTISONE; HYDROXYZINE; IMMUNOGLOBULIN E; MOMETASONE FUROATE; TACROLIMUS; TETRACOSACTIDE;

ADRENAL SUPPRESSION; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; CUSHING SYNDROME; DRUG MISUSE; DRUG POTENCY; DRUG WITHDRAWAL; FAILURE TO THRIVE; FEMALE; GROWTH RETARDATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFANT; LONG TERM CARE; PRIORITY JOURNAL; PROBABILITY; PRURITUS; SIDE EFFECT; SUPERINFECTION; THYROID FUNCTION TEST;

ADMINISTRATION, CUTANEOUS; BONE DENSITY; CUSHING SYNDROME; DERMATITIS, ATOPIC; DRUG MONITORING; FAILURE TO THRIVE; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFANT; MALE; PITUITARY-ADRENAL SYSTEM; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 57449111481     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L067     Document Type: Article

References (35)

1. Brown S, Reynolds NJ. Atopic and non-atopic eczema. BMJ 2006;332: 584-8.
2. Abeck D, Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol 2000;1:41-6.
3. Granlund H. Treatment of childhood eczema. Paediatr Drugs 2002;4:729-35.
4. Darsow U, Lübbe J, Taïeb A, et al.; European Task Force on Atopic Dermatitis. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005;19:286-95.
5. Ohman EM, Rogers S, Meenan FO, McKenna TJ. Adrenal suppression following low-dose topical clobetasol propionate. J R Soc Med 1987;80:422-4.
6. Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998;38:318-21.
7. Gen R, Akbay E, Sezer K. Cushing syndrome caused by topical corticosteroid: a case report. Am J Med Sci 2007;333:173-4.
8. Abma EM, Blanken R, De Heide LJ. Cushing's syndrome caused by topical steroid therapy for psoriasis. Neth J Med 2002;60:148-50.
9. Teelucksingh S, Bahall M, Coomansingh D, Suite M, Bartholomew C. Cushing's syndrome from topical glucocorticoids. West Indian Med J 1993;42:77-8.
10. Oelkers W. Adrenal insufficiency. N Engl J Med 1996;335:1206-12.
11. Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003;148:128-33.
12. Schafer-Korting M, Schmid MH, Korting HC. Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept. Drug Saf 1996;14:375-85.
13. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol 1996;35:615-9.
14. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15; quiz 16-8.
15. Schnopp C, Holtmann C, Stock S. et al. Topical steroids under wet-wrap dressings in atopic dermatitis - a vehicle-controlled trial. Dermatology 2002;204:56-9.
16. Devillers AC, Oranje AP. Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 2006;154:579-85.
17. Rutter N. Drug absorption through the skin: a mixed blessing. Arch Dis Child 1987;62:220-1.
18. Turpeinen M, Lehtokoski-Lehtiniemi E, Leisti S, Salo OP. Percutaneous absorption of hydrocortisone during and after the acute phase of dermatitis in children. Pediatr Dermatol 1988;5:276-9.
19. Mancini AJ. Skin. Pediatrics 2004;113:1114-9.
20. 14C cortisol in man. J Invest Dermatol 1967;48:181-3.
21. Burks W. Skin manifestations of food allergy. Pediatrics 2003;111:1617-24.
22. Hill DJ, Sporik R, Thorburn J, Hosking CS. The association of atopic dermatitis in infancy with immunoglobulin E food sensitization. J Pediatr 2000;137:475-9.
23. Guillet MH, Guillet G. [Allergologie survey in 251 patients with moderate or severe dermatitis. Incidence and value of the detection of contact eczema, food allergy or sensitization to air-borne allergens] French. Ann Dermatol Venereol 1996;123:157-64.
24. Agostoni C, Grandi F, Scaglioni S, et al. Growth pattern of breastfed and nonbreastfed infants with atopic dermatitis in the first year of life. Pediatrics 2000;106:e73.
25. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31.
26. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 2000;106:e8.
27. Kristmundsdottir F, David TJ. Growth impairment in children with atopic eczema. J R Soc Med 1987;80:9-12.
28. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
29. Cherian MP, AbdulJabbar M. Cushing's syndrome and adrenal suppression from percutaneous absorption of clobetasol propionate in infants. Saudi Med J 2001;22:1139-41.
30. Siklar Z, Bostanci I, Atli O, Dallar Y. An infantile Cushing syndrome due to misuse of topical steroid. Pediatr Dermatol 2004;21:561-3.
31. Ermis B, Ors R, Tastekin A, Ozkan B. Cushing's syndrome secondary to topical corticosteroids abuse. Clin Endocrinol (Oxf) 2003;58:795-6.
32. Güven A, Gülümser O, Ozgen T. Cushing's syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse? J Pediatr Endocrinol Metab 2007;20:1173-82.
33. Ozon A, Cetinkaya S, Alikasifoglu A, Gonc EN, Sen Y, Kandemir N. Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab 2007;20:219-25.
34. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic- pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000;105:794-9.
35. Haeck IM, Timmer-de Mik L, Lentjes EG, et al. Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accused. Br J Dermatol 2007;156:979-85.